|Day Low/High||85.85 / 86.63|
|52 Wk Low/High||74.97 / 96.31|
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Here are two I think will bounce back before the end of the year.
These names are showing bullish or bearish reversal patterns over the past week.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
Happy Friday! These are the stories you must know ahead of the opening bell.
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
A look at possible second-quarter M&A activity in the biotech sector.
Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.
U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.
John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.
Markets are down across the board in the first hour of trading. However, we are nicely off the lows of the day. Financials are bucking the early downward tilt of the market and are up today. This sector continues to benefit from slowly rising intere...
Is CVS's planned acquisition of Aetna just a reaction to Amazon's dive into healthcare? Here's what we know so far.
Entering GE too early has its costs, but there are ways to mitigate them.
European markets opened flat as investors await the European Central Bank meeting
European stock markets are priced almost to perfection ahead of an earnings deluge.
Biotech investors should keep a close eye on the progress in this huge potential market.
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
There are nearly too many surging sectors to count.
Novartis has seen some very aggressive buying the past five months -- time to join in.
Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.
Reports from DuPont and Alibaba looked promising for the markets on Wednesday.